Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Pfizer is one of the world’s largest pharmaceutical companies, but at $22.59 per share as of this writing, the stock trades at its lowest levels in 13 years.Shares are down 19% over the past ...

Still, Pfizer stock has fallen 10% year to date and hasn’t provided the defensive hedge that many of its Zacks Large Cap Pharmaceutical peers have been able to provide, such as AbbVie ABBV ...

saw its stock rise by 3.75% in pre-market trading, reflecting investor optimism about its earnings performance and strategic initiatives. Want deeper insights? InvestingPro analysis reveals 10+ ...

Pfizer stock (NYSE: PFE) has recently announced its Q1 results, reporting revenues that fell short of expectations while earnings surpassed analyst predictions. The company disclosed revenue of $ ...